Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer.
Curry
Eardie A
EA
Purdue University School of Pharmacy and Pharmacal Sciences, West Lafayette and Indiana University School of Medicine, Indianapolis, Indiana, USA.
Sweeney
Christopher J
CJ
D000230:Adenocarcinoma / Q000188:drug therapy*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage* / Q000009:adverse effects; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D005500:Follow-Up Studies; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D017273:Goserelin / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D016729:Leuprolide / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D018931:Antineoplastic Agents, Hormonal; D017273:Goserelin; D007987:Gonadotropin-Releasing Hormone; D016729:Leuprolide